Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10920730 | 0.92 | GPR119 (0.64) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2592011 | 0.88 | GPR119 (0.98) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2587403 | 0.87 | GPR119 (1.00) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2580741 | 0.86 | GPR119 (0.82) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2590274 | 0.86 | GPR119 (0.82) | GPR119PDE3BPDE3A | |
| SCHEMBL2590202 | 0.85 | GPR119 (0.80) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2590585 | 0.85 | GPR119 (1.00) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2583302 | 0.84 | GPR119 (0.78) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2583307 | 0.83 | GPR119 (0.77) | GPR119PDE3BPDE3APDE4APDE4B | |
| SCHEMBL2590881 | 0.80 | GPR119 (0.79) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | claimed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | claimed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | claimed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | claimed |
| US-8772323-B2 | Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-08 | — | — | US | disclosed |
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| EP-2566864-A2 | PYRIDAZINONES AS GPR119 AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011138427-A2 | PYRIDAZINONES AS GPR119 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | WO | disclosed |
| EP-0196005-B1 | PYRIDAZINONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172323-A1 | PYRIDAZINONES AS GPR119 AGONISTS | GPR65, GPR119, GPR55 | GPR119 2/4885PDE3B 915/4885PDE3A 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.